858 Companies

Access all companies

Find technology partners quickly.

Spotfolio tracks over one million companies in technology industries.

There are 858 companies in the field of Biopharma on spotfolio that produce or deliver products, that utilize or research technologies or that are otherwise engaged in topics such as Clinical, Drug, Therapies, Patients, Therapeutic, Treatment, Disease, Research .

Start-ups (145)

Early-stage companies (233)

Established companies (415)

The majority of these companies is located in the following countries.

United States (491)

United Kingdom (62)

Canada (36)

China (34)

Example Companies

Find companies in your area

Intra-Cellular Therapies Intra-Cellular Therapies, Inc.

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update Second Quarter - Intra-Cellular Therapies Reports Second ...

Intra-Cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update 2019 Fourth Quarter - Intra-Cellular Therapies Reports ...

Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results Second Quarter - Intra-Cellular Therapies Provides ...

Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update 2018 Fourth Quarter - Intra-Cellular Therapies Reports ...

Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results Second Quarter - Intra-Cellular Therapies Provides ...

Intra-Cellular Therapies Reports First Quarter 2018 Financial Results and Provides Corporate Update 2017 Fourth Quarter - Intra-Cellular Therapies Reports

Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast PDF Version October 1, 2020 Intra-Cellular Therapies Announces ...

Intra-Cellular Therapies to Present at the Morgan Stanley 18th Annual Global Healthcare Conference PDF Version September 14, 2020 Intra-Cellular Therapies to Present ...

10, 2020 Intra-Cellular Therapies Prices Public Offering of Common Stock PDF Version September 9, 2020 Intra-Cellular Therapies Announces Proposed Public ...

Offering of Common Stock PDF Version September 9, 2020 Intra-Cellular Therapies Announces Positive Topline Results from Study 402 Evaluating Lumateperone ...

Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update PDF Version August 4, 2020 Intra-Cellular Therapies to Host ...

Conference Call and Webcast PDF Version June 29, 2020 Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients

Neuropore Therapies Neuropore Therapies, Inc

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Return to the homepage News News Neuropore Therapies Licenses Autophagy Modulators to Global Cancer Technology for Treatment of Cancers and Other Life-Threatening ...

Life-Threatening Diseases September 29, 2020 Neuropore Therapies, Inc. announced today that it has licensed two mechanistically distinct classes of potent ...

Technology. /media/news/neuropore-therapies-and-benevolentai-enter-strategic-collaboration9861.htm Neuropore Therapies Receives Grant from The ALS Asso ...

Association/media/news/neuropore-therapies-and-benevolentai-enter-strategic-collaboration9861.htmFebruary 17, 2020 Neuropore Therapies, Inc., a clinical stage ...

Development Program. Neuropore Therapies Completes Phase 1 Trial in Healthy Volunteers with NPT520-34 /media/news/neuropore-therapies-and-benevolentai-enter- ...

strategic-collaboration9861.htmJanuary 13, 2020 Neuropore Therapies, Inc., a clinical stage biopharmaceutical company announced today that it has successfully

Check back for the latest media updates from Neuropore. News Neuropore Therapies Licenses Autophagy Modulators to Global Cancer Technology for Treatment ...

Cancers and Other Life-Threatening Diseases September 29, 2020 Neuropore Therapies, Inc. announced today that it has licensed two mechanistically distinct ...

s99821021010385.htm Neuropore Therapies Receives a Grant from The ALS Association February 17, 2020 Neuropore Therapies, Inc., a clinical stage biopharmaceutical ...

Program. Neuropore Therapies Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34 January 13, 2020 Neuropore Therapies, Inc., a clinical ...

lateral sclerosis. Neuropore Therapies Appoints Dr. Joseph S. McCracken to Board of Directors October 29, 2019 Neuropore Therapies, Inc., a clinical stage ...

Treatment of Amyotrophic Lateral Sclerosis August 14, 2019 Neuropore Therapies, Inc. announced announced today that it has received orphan drug designation

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

partners aim to develop safer, more tolerable and more effective cytokine therapies for single agent and novel combinations with Boehringer Ingelheim’s innovative ...

cancer vaccine, oncolytic virus, T cell engager and myeloid-targeting therapies Ingelheim, Germany and San Diego, California – 27 February 2020 – Boehringer ...

breakthrough therapies for cancer patients with Trutino’s unique knowledge and expertise in increasing the safety and efficacy of cytokine therapies. “Developing ...

innovative scientific approaches and is a leader in bringing novel cancer therapies to market. This global partnership validates the broad potential of our ...

cytokine therapies that can be delivered systemically and activated locally. Together, we can rapidly develop a new generation of cytokine therapies to address ...

exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim

partners aim to develop safer, more tolerable and more effective cytokine therapies for single agent and novel combinations with Boehringer Ingelheim’s innovative ...

cancer vaccine, oncolytic virus, T cell engager and myeloid-targeting therapies Boehringer Ingelheim Press Release – 2/27/2020 Ingelheim, Germany and ...

breakthrough therapies for cancer patients with Trutino’s unique knowledge and expertise in increasing the safety and efficacy of cytokine therapies “Developing ...

innovative scientific approaches and is a leader in bringing novel cancer therapies to market. This global partnership validates the broad potential of our ...

cytokine therapies that can be delivered systemically and activated locally. Together, we can rapidly develop a new generation of cytokine therapies to address ...

exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim

Genprex Genprex, Inc.

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have ...

options. Pipeline We are developing gene therapies for patients with cancer and diabetes to bring new therapies to large patient populations. Our lead product ...

is designed to be administered in combination with other therapies, including targeted therapies and immunotherapies, for non-small cell lung cancer. Management ...

About Us At Genprex, we are committed to developing life-changing gene therapies for patients with cancer and diabetes through unique, innovative science ...

with limited or no treatment options to have access to new and advanced therapies to more effectively treat their disease. What they’re saying In the Media

ONCOPREX® nanoparticle delivery system combined with approved targeted therapies and immunotherapies. This enables us to offer hope to large patient populations ...

populations who would otherwise not be candidates for those therapies or who have become resistant to them. Oncology Combination Treatment Approach Our ...

candidate for non-small cell lung cancer (NSCLC), is combined with targeted therapies such as Tarceva (erlotinib) or Tagrisso (osimertinib) or with immunotherapies ...

either drug alone. We believe that by combining REQORSA with targeted therapies and immunotherapies, we can extend the benefit of these approved lung cancer ...

refer to our Pipeline and Clinical Trials pages. Targeted Therapies Targeted therapies work by targeting the cancer or disease’s specific gene, protein ...

contributes to the disease while sparing normal tissue. Unfortunately, targeted therapies require patients to have an activating genetic mutation specific to the

Loxo Oncology Loxo Oncology, Inc.

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

available therapies. Loxo Oncology was founded to address this unmet medical need. Our product pipeline consists of investigational therapies that are currently ...

how these investigational therapies work, which cancers in humans are most likely to benefit from these investigational therapies, and how to understand fully ...

the investigational therapies. Patients with cancer often exhaust standard treatment options and seek out investigational therapies being tested in clinical ...

clinical trials. Sometimes these investigational therapies may be available to them as part of a clinical trial. People who take part in clinical trials help ...

help society by contributing to medical research, the development of new therapies, and the advancement of patient care. Other times, patients may not be ...

physicians can request drug companies like Loxo to make these investigational therapies available to their patients outside of clinical trials. Loxo Oncology

to Investigational Therapies Loxo Oncology at Lilly is committed to helping patients who have not responded to available therapies and may benefit from ...

from its investigational therapies. For more information about our Policy for Access to Investigational Agents, please click here. Our Clinical Trials

Use detailed technology terms.

Only spotfolio allows for searching with detailed technology terms, as we provide you with all topics that technology companies talk about.

Companies addressing these topics might be of specific interest to you, as they share more specific, niche topics.

Use Cases

Register now

Why Technology Scouting?

Technology scouting is the basis for your innovation management, identifies new technological developments as early as possible and protects you from disruptive business models.

Identify technology partners

Boost your market research

Look beyond major players

Build long and short lists

Collect technology leaders, providers, start ups and potential new partners in lists via simple tagging to take further steps with your team.